Celgene reports positive survival data from multiple myeloma study; EC approves Bayer's Xarelto; Atox reports positive data, plans to raise funds;

Conversations on Twitter :

Could a troubled fish oil market bring down Amarin? Debate on Amarin's outlook going forward.
Poll of institutional investors shows skepticism of blockbuster potential for obesity drugs by Arena, Vivus, and Orexigen. But are these reliable opinions?
#PCORI: Board members of the Patient-Centered Outcomes Research Institute live-tweet insights from yesterday's meeting.

 @FierceBiotech: GSK's new Promacta approval triggers a spike for Ligand shares. News | Follow @FierceBiotech

 @JohnCFierce: Celgene, Sanofi execs in (another) biopharma insider trading case. Is it that hard for insiders to get away with this? Story | Follow @JohnCFierce

 @RyanMFierce: Rare disease R&D and academic/pharma tie-up trends have melded in Shire's new alliance with Boston Children's. More | Follow @RyanMFierce

> Celgene ($CELG) reports that its experimental cancer drug pomalidomide along with a low dose of a standard therapy significantly extended the lives of late-stage multiple myeloma patients who had failed an average of 5 therapies. Story

> Bayer's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for the treatment of pulmonary embolism and the prevention of recurrent deep vein thrombosis and PE in adults. Release

> Globes reports that Israel's Atox Bio is out raising funds as it reports positive data from a Phase IIa study of AB103 for necrotizing soft tissue infections. Story

> Eli Lilly ($LLY) has moved up to the #51 slot on the S&P 500, taking Boeing's place on the list. Story

Pharma News

@FiercePharma: New special report for a short week: The world's 20 best-selling generic drugs. Not just the usual suspects. Special Report | Follow @FiercePharma

> Bayer says trumping Reckitt's $1.4B Schiff bid is too rich. Story

> Overnight success proves elusive for oral MS drugs. News

> Sanofi, Celgene execs charged in insider trading ring. Article

Medical Device News

 @FierceMedDev: Spread the word - we're highlighting some of the top M&A targets in devices and diagnostics. Special Report | Follow @FierceMedDev

 @MarkHFierce: Could the device tax lead to supply problems? Item | Follow @MarkHFierce

 @DamianFierce: The SEC says employees of Stryker, Celgene and Sanofi carried on a complex insider trading scam. Report | Follow @DamianFierce

> Push to create pediatric medical devices brings Cincinnati Children's to Israel. Story

> Medtronic sees profit slip despite uptick in revenue. News